Alvotech ALVO PHARMA
Company Overview
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Why Investors Should Care
Revenue has grown at a 91.8% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $586.32M (+19.7% YoY); net profit $27.92M.
- Trailing 12 Months Year-on-year growth — revenue -38.9%, earnings -99.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 91.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 91.85% |
| 1 Year: | -38.90% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -99.00% |
Stock Price Performance
| 1 Year: | -42.08% |
| 6 Months: | +29.10% |
| 3 Months: | +22.41% |
| 1 Month: | +36.22% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)67.30 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 91.8% over 5 years.
CONS
- Trading 42.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALVO Alvotech PHARMA | 5.19 | -8.37 | $1.85B | 0.00% | 6.61% | -9.81% | 91.85% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 132.76M | 173.24M | 113.74M | 166.57M | 105.86M |
| Cost of Revenue | - | 65.45M | 73.83M | 35.01M | 61.28M | 46.09M |
| Gross Profit | - | 67.32M | 99.41M | 78.74M | 105.29M | 59.78M |
| Operating Expenses | - | 56.74M | 81.36M | 77.42M | 57.04M | 50.10M |
| Operating Income | - | 10.58M | 18.06M | 1.31M | 48.26M | 9.67M |
| EBITDA | - | 137.22M | 51.74M | 43.57M | 78.54M | 52.08M |
| Interest Expense | - | 35.54M | 33.53M | 39.38M | 28.42M | 40.81M |
| Pretax Income | - | 93.42M | 9.31M | -6.09M | 39.70M | 986.00K |
| Tax Provision | - | -16.26M | -22.73M | -835.00K | 148.25M | -44.00K |
| Net Income | - | 109.68M | 32.04M | -5.25M | -108.55M | 1.03M |
| Diluted EPS | - | 0.35 | - | - | - | 0.00 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 83.03M | 91.43M | 489.68M | 586.32M |
| Cost of Revenue | - | 64.09M | 160.86M | 185.31M | 235.56M |
| Gross Profit | - | 18.93M | -69.42M | 304.37M | 350.76M |
| Operating Expenses | - | 365.38M | 285.44M | 234.73M | 272.56M |
| Operating Income | - | -346.44M | -354.86M | 69.64M | 78.21M |
| EBITDA | - | -453.76M | -493.67M | -32.27M | 311.07M |
| Interest Expense | - | 77.47M | 133.17M | 153.99M | 136.87M |
| Pretax Income | - | -551.65M | -651.05M | -217.56M | 136.35M |
| Tax Provision | - | -38.07M | -99.32M | 14.30M | 108.43M |
| Net Income | - | -513.58M | -551.73M | -231.86M | 27.92M |
| Diluted EPS | - | -2.60 | -2.43 | -0.87 | 0.10 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 828.44M | 950.09M | 1.22B | 1.49B |
| Current Assets | - | 230.74M | 194.84M | 455.02M | 574.01M |
| Cash & Equivalents | - | 66.43M | 11.16M | 51.43M | 172.36M |
| Inventory | - | 71.47M | 74.43M | 127.89M | 220.05M |
| Receivables | - | 32.97M | 41.29M | 160.22M | 69.74M |
| Total Liabilities | - | 1.39B | 1.88B | 1.63B | 1.77B |
| Current Liabilities | - | 167.29M | 260.95M | 193.40M | 304.08M |
| Long Term Debt | - | 744.65M | 922.13M | 1.04B | 1.26B |
| Total Debt | - | 805.10M | 1.08B | 1.19B | 1.45B |
| Total Equity | - | -564.42M | -932.49M | -412.77M | -284.49M |
| Shares Outstanding | - | 248.65M | 289.73M | 324.80M | 334.04M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -312.39M | -312.19M | -236.84M | -50.20M |
| Investing Cash Flow | - | -63.54M | -46.34M | -18.87M | -104.22M |
| Financing Cash Flow | - | 424.91M | 301.32M | 297.31M | 270.83M |
| Capital Expenditure | - | -49.00M | -46.47M | -57.00M | -96.13M |
| Free Cash Flow | - | -361.39M | -358.66M | -293.84M | -146.33M |
| Net Change in Cash | - | 48.98M | -57.21M | 41.59M | 116.42M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 22.8% | -75.9% | 62.2% | 59.8% |
| Operating Margin % | - | -417.3% | -388.1% | 14.2% | 13.3% |
| Net Margin % | - | -618.6% | -603.4% | -47.3% | 4.8% |
| ROE % | - | 91.0% | 59.2% | 56.2% | -9.8% |
| ROCE % | - | -52.4% | -51.5% | 6.8% | 6.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Rubric Capital Management LP | 5.02% | 15.68M | $92.02M |
| 2 | Millennium Management Llc | 1.37% | 4.26M | $25.03M |
| 3 | Bracebridge Capital, LLC | 1.29% | 4.04M | $23.71M |
| 4 | Vanguard Capital Management LLC | 1.18% | 3.69M | $21.66M |
| 5 | Farallon Capital Management LLC | 0.92% | 2.86M | $16.79M |
| 6 | Citadel Advisors Llc | 0.55% | 1.73M | $10.14M |
| 7 | Price (T.Rowe) Associates Inc | 0.45% | 1.42M | $8.33M |
| 8 | Blackrock Inc. | 0.43% | 1.33M | $7.79M |
| 9 | Littlejohn & Co LLC | 0.42% | 1.32M | $7.74M |
| 10 | Vanguard Fiduciary Trust Co | 0.32% | 998.60K | $5.86M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALVO
Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations
REYKJAVIK, Iceland, August 31, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and D…
Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations
REYKJAVIK, Iceland, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the…
Has Alvotech (NasdaqGM:ALVO) Fallen Below Fair Value After Its Deal?
Alvotech stock has fallen about 50% over the past three years, yet the valuation checks currently lean cheap and the market is reacting positively to fresh licensing deals and regulatory progress. Over the past three years the share price i…
Why Alvotech (ALVO) Is Up 11.7% After Expanding Biosimilar Deal With Lotus Pharmaceutical
In August 2026, Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical for biosimilar candidates AVT34 (Imfinzi) and AVT87 (Hemlibra) across the United States and eight Asian markets, with potential conside…
Bank of America sees major upside in this biotech stock
A major Wall Street firm says a regulatory shift and coming launches could change the setup for one biosimilar developer.
Alvotech to present at upcoming investor conferences in September
REYKJAVIK, ICELAND (August 27, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Robert Wessman, Fo…
ALVO — Frequently Asked Questions
What is the current share price of Alvotech (ALVO)?
As of 2026-09-19 21:16 PDT, Alvotech (ALVO) trades at $5.19 on NasdaqGM. Its 52-week range is $3.00 to $9.00.
What is the market capitalisation of ALVO?
Alvotech (ALVO) has a market capitalisation of $1.85B on NasdaqGM.
What is the P/E ratio of ALVO?
ALVO trades at a trailing price-to-earnings (P/E) ratio of -8.37. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -9.70.
What is the return on equity (ROE) of ALVO?
ALVO has a return on equity (ROE) of -9.81%. Its return on capital employed (ROCE) is 6.61%.
Is ALVO a good stock to buy?
This page provides a data-driven analysis of Alvotech (ALVO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.